Compare · MIRA vs NVO
MIRA vs NVO
Side-by-side comparison of MIRA Pharmaceuticals Inc. (MIRA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MIRA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 4640.6x MIRA ($41.2M).
- Over the past year, MIRA is down 18.8% and NVO is down 44.8% - MIRA leads by 26.0 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 6 for MIRA).
- NVO has more recent analyst coverage (25 ratings vs 0 for MIRA).
- Company
- MIRA Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $0.99-1.08%
- $43.48+1.61%
- Market cap
- $41.2M
- $191.15B
- 1M return
- -0.09%
- -7.60%
- 1Y return
- -18.85%
- -44.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 6
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MIRA
- SEC Form 3 filed by new insider Mushak Andriy
- MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
- MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
- SEC Form 10-Q filed by MIRA Pharmaceuticals Inc.
- MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
- MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
- MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care